Key Takeaways PACB selected by Basecamp for Trillion Gene Atlas using HiFi sequencing on Revio.Basecamp project spans about 100,000 samples across 31 countries for EDEN AI model training.PACB tech enables accurate, long-read sequencing to support large-scale AI-driven biology.Pacific Biosciences of California, Inc. (PACB) , popularly known as PacBio, recently announced that Basecamp Research has selected its HiFi sequencing technology on the Revio system to support the ambitious Trillion Gene Atlas initiati ...

Financial Data and Key Metrics Changes - In Q4 2025, total revenue grew 14% year-over-year to $44.6 million, with a sequential increase of 16% [7][27] - For the full year 2025, total revenue reached $160 million, representing a 4% growth over 2024 [7][30] - Non-GAAP gross margin improved to 40% in Q4 2025, up from 31% in Q4 2024, and for the full year, it was also 40%, compared to 33% in 2024 [31][24] - Non-GAAP operating expenses decreased to $56.2 million in Q4 2025, down 18% year-over-year, and for the full year, they were $229.9 million, down from $289.2 million in 2024 [32][24] - Cash burn improved from $214 million in 2023 to $105 million in 2025, with approximately $280 million in cash and investments at year-end [25][34] Business Line Data and Key Metrics Changes - Consumable revenue in Q4 2025 increased 15% year-over-year to $21.6 million, driven by an increase in the installed base and consistent system utilization [27][28] - Instrument revenue rose 13% in Q4 to $17.3 million, primarily due to increased shipments of Vega systems [28] - For the full year 2025, consumables revenue increased 16% to $82 million, while instrument revenue decreased 18% to $53.8 million [30] Market Data and Key Metrics Changes - Revenue from the Americas increased 3% to $20.7 million in Q4 2025, while Asia Pacific revenue rose 4% to $9.3 million, and EMEA revenue surged 45% to $14.6 million [29][10] - EMEA's strong growth was attributed to increased Vega instrument shipments and higher Revio consumables as clinical customers transitioned from pilot testing to broader adoption [11][29] Company Strategy and Development Direction - The company aims to enhance the economics of HiFi sequencing through the launch of SparkNex and multi-use smart cells, targeting increased market penetration [37] - Focus areas include accelerating clinical adoption in rare disease, oncology, and carrier screening, as well as enabling population-scale sequencing studies [37] - The company plans to leverage AI to unlock biological insights from multi-omic HiFi data [37] Management's Comments on Operating Environment and Future Outlook - Management anticipates continued growth in clinical markets, particularly in rare disease and whole genome sequencing, despite a challenging academic funding environment [11][54] - The outlook for 2026 projects revenue between $165 million and $180 million, representing approximately 8% growth at the midpoint [34] - Management expects non-GAAP gross margin to improve by 100-400 basis points in 2026, driven by a higher consumables mix and the introduction of SparkNex [35] Other Important Information - The company sold its short-read sequencing assets for net proceeds of approximately $48 million, strengthening its balance sheet and extending its cash runway [26] - The company is committed to supporting existing customers during the transition period following the divestment of short-read assets [26] Q&A Session Summary Question: What should we expect for Revio pull-through and consumables growth? - Management expects SparkNex to lower sample costs, likely increasing utilization and expanding market share, while maintaining pull-through in the range of $225K-$250K [41][43] Question: What is the outlook for clinical growth outside the U.S.? - Management sees strong growth in clinical markets, particularly in EMEA, with significant movement from pilot phases to production [53] Question: Where are the biggest opportunities for OpEx reduction? - Management plans to focus on managing G&A expenses and R&D while continuing to reduce production costs through insourcing [66][68] Question: What impact will the short-read divestment have on costs? - Management indicated that while there won't be substantial additional costs taken out immediately, the divestment will provide a tailwind to gross margin over time [72] Question: How does long-read sequencing compare to standard care in terms of cost? - Long-read sequencing is expected to provide better diagnostic yield, faster turnaround times, and lower overall costs by consolidating multiple tests into one [74]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue grew 14% year-over-year to $44.6 million, with a sequential increase of 16% [7][26] - For the full year 2025, total revenue reached $160 million, representing a 4% growth over 2024 [7][30] - Non-GAAP gross margin improved to 40% in Q4 2025, up from 31% in Q4 2024, and also increased from 33% in 2024 to 40% in 2025 [31][23] - Non-GAAP operating expenses decreased from $355 million in 2023 to $230 million in 2025, a 35% reduction [23][32] - Cash burn improved from $214 million in 2023 to $105 million in 2025, representing a 51% improvement [24] Business Line Data and Key Metrics Changes - Consumable revenue in Q4 2025 increased 15% year-over-year to $21.6 million, driven by an increase in the installed base and consistent system utilization [26][30] - Instrument revenue increased 13% in Q4 2025 to $17.3 million, primarily due to an increase in Vega systems [27] - For the full year 2025, consumables revenue grew 16% to $82 million, while instrument revenue decreased 18% to $53.8 million [30] Market Data and Key Metrics Changes - In Q4 2025, Americas revenue increased 3% to $20.7 million, Asia Pacific revenue increased 4% to $9.3 million, and EMEA revenue surged 45% to $14.6 million [10][29] - EMEA's strong growth was attributed to increased Vega instrument shipments and higher Revio consumables as clinical customers shifted to broader clinical adoption [11][29] Company Strategy and Development Direction - The company aims to improve the economics of HiFi sequencing through the launch of SparkNex and multi-use smart cells [38] - Focus on accelerating clinical adoption in rare disease, oncology, and carrier screening, while enabling population-scale sequencing studies [38] - The strategy includes leveraging AI to unlock biological insights and driving innovation in sequencing technology [38] Management's Comments on Operating Environment and Future Outlook - Management expects 2026 revenue to be in the range of $165 million to $180 million, representing approximately 8% growth at the midpoint [11][34] - The company anticipates continued pressure from the academic funding environment, particularly in the Americas, impacting capital spending [34][35] - Management is optimistic about the growth in clinical markets, especially in EMEA, despite the challenges in the academic sector [53] Other Important Information - The company sold its short-read sequencing assets for net proceeds of approximately $48 million, strengthening its balance sheet [25] - The introduction of SparkNex is expected to enhance gross margins and improve the overall financial profile [21][23] Q&A Session Summary Question: What should we expect OUS to do this year from a clinical growth perspective? - Management noted strong growth in clinical markets, particularly in rare disease and whole genome sequencing, especially in EMEA, with customers moving from pilot phases to production [53] Question: Where's the biggest opportunity to reduce OpEx spending this year? - Management indicated a focus on managing G&A expenses and R&D while maintaining critical programs, with a goal to reduce non-headcount-related spending [66] Question: Did you see any budget flush, particularly from Europe in full Q25? - Management did not observe significant budget flush but noted some opportunistic purchasing [51][52]

Financial Performance - Total revenue for Q3 2025 was $3844 million, a decrease of 4% year-over-year (Y/Y)[12, 54] - Consumable revenue reached $213 million, showing a 15% Y/Y increase and a 12% quarter-over-quarter (Q/Q) increase[12, 36] - Instrument revenue was $113 million, a decrease of 33% Y/Y and 20% Q/Q, attributed to lower Vega shipments, especially in Europe[12, 36] - Non-GAAP gross profit was $162 million with a gross margin of 42%, compared to $130 million and 33% in Q3 2024, respectively[38] - Non-GAAP operating expenses were $539 million, lower than the $624 million in Q3 2024[38] - Non-GAAP net loss was $368 million, an improvement from the $460 million loss in Q3 2024[38] - Cash and investments stood at $2987 million as of September 30, 2025[38, 60] - The company narrows its FY 2025 revenue guidance to $155-$160 million[39] Product and Technology Updates - Revio system shipments continue, with approximately 75% going to new customers[12] - Vega system shipments also persist, with about 60% going to new customers[12] - Sequel® II CNDx received Class III Medical Device Registration approval in China[16] - SPRQ-Nx chemistry is planned for launch in 2026, aiming for a cost of less than $300 per genome at scale[27] Clinical and Research Highlights - HiFi sequencing was selected for the National Institute on Aging's Long Life Family Study, involving up to 7800 whole genomes and epigenomes[24] - HiFi sequencing was selected for the Korean Pangenome Reference Project led by KCDC, targeting over 1000 Korean genomes[26]

Core Viewpoint - PacBio has entered a strategic distribution agreement with Haorui Gene to enhance the adoption of its HiFi sequencing technology in China, particularly in clinical diagnostics and precision medicine [1][2][4]. Company Summary - The partnership with Haorui Gene allows PacBio to access a broader clinical laboratory network in China, which is expected to accelerate the adoption of its long-read sequencing platforms [1][4]. - PacBio's market capitalization is currently $294.4 million, with an anticipated earnings growth of 16.8% by 2025 [5]. - Following the announcement of the distribution agreement, PacBio's shares closed at $1.12, reflecting a year-to-date decline of 48.6% compared to the industry’s 9.7% decline [3]. Industry Summary - The global long-read sequencing market is projected to grow from an estimated size of $538.9 million in 2024, with a compound annual growth rate (CAGR) of 20.12% from 2025 to 2030 [12]. - Key drivers of market growth include the increasing prevalence of genetic diseases, the rise of personalized medicine, and advancements in technology leading to new sequencing methods [13].

Core Insights - PacBio reported an adjusted loss per share of 15 cents for Q1 2025, an improvement from a loss of 26 cents in the same quarter last year, exceeding the Zacks Consensus Estimate by 21.1% [1] - Total revenues for the first quarter were $37.2 million, down 4.3% year over year, but above the Zacks Consensus Estimate by 6.2% [2] - The company experienced a decline in revenues across the Americas and Asia-Pacific regions, while the EMEA region saw an 11% increase in revenues [3][4][5] Revenue Breakdown - Revenues from the Americas were $16.3 million, an 8% decline year over year due to government funding challenges [3] - Asia-Pacific revenues totaled $11.6 million, reflecting a 9% decline, although consumables performed well due to increased utilization of the Revio system [4] - EMEA revenues reached $9.3 million, an 11% increase, driven by strong Revio placements in the hospital and clinic segment [5] Segment Analysis - Total product revenues were $31.1 million, down 11.1% year over year, with instrument revenues significantly impacted, falling 42.1% to $11 million [6] - Consumables revenues increased by 25.6% to $20.1 million, with annualized Revio pull-through per system at $236,000 [7] - Service and other revenues rose 57.9% to $6 million, attributed to increased service contract revenues related to Revio [7] Margin and Expense Trends - Adjusted gross profit increased 18.8% year over year to $15 million, with adjusted gross margin expanding by 700 basis points to 40% [8] - Sales, general, and administrative expenses decreased by 8.2% to $40.2 million, while research and development expenses fell 33.2% to $29.1 million [8] - Total adjusted operating loss was $54.2 million, an improvement from $74.6 million in the prior year [9] Financial Position - At the end of Q1 2025, PacBio had cash and investments totaling $343.1 million, down from $389.9 million at the end of 2024 [10] Guidance and Outlook - For Q2 2025, PacBio expects revenues to be flat compared to Q1 2025, with a Zacks Consensus Estimate of $36.9 million [11] - The company revised its 2025 revenue outlook to between $150 million and $170 million, down from the previous guidance of $155 million to $170 million [12] Strategic Initiatives - PacBio initiated a company-wide restructuring plan aimed at reducing operating expenses by approximately $45 million to $50 million by the end of 2025 [14] - The company entered a licensing agreement to enhance methylation detection capabilities within its HiFi sequencing platform, which is expected to expand applications in cancer research and rare disease diagnostics [15] - Performance was impacted by macroeconomic challenges, including reduced academic funding and U.S.-China tariffs, leading to a decline in Revio system shipments [16]